Search hospitals > North Carolina > Statesville

Novant Health Cancer Institute - Statesville

Claim this profile
Statesville, North Carolina 28625
Global Leader in Breast Cancer
Global Leader in Breast cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
39 reported clinical trials
6 medical researchers
Photo of Novant Health Cancer Institute - Statesville in StatesvillePhoto of Novant Health Cancer Institute - Statesville in Statesville

Summary

Novant Health Cancer Institute - Statesville is a medical facility located in Statesville, North Carolina. This center is recognized for care of Breast Cancer, Breast cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Novant Health Cancer Institute - Statesville is involved with conducting 39 clinical trials across 85 conditions. There are 6 research doctors associated with this hospital, such as Judith O. Hopkins, Demetria I. Jacks, Volker W. Stieber, and Joshua Trinidad.

Area of expertise

1Breast Cancer
Global Leader
Novant Health Cancer Institute - Statesville has run 15 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 positive
PR positive
2Breast Cancer
Global Leader
Novant Health Cancer Institute - Statesville has run 11 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative

Top PIs

Clinical Trials running at Novant Health Cancer Institute - Statesville

Lung Cancer
Breast Cancer
Small Cell Lung Cancer
Breast cancer
Cancer
Lung Carcinoma
Non-Small Cell Lung Cancer
Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Novant Health Cancer Institute - Statesville?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security